---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035848"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:51:47.045973+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# X4 reports Q2 net income $90.8M on PRV sale; first XOLREMDI sales $0.6M

## Summary
- Q2 net income $90.8M vs net loss $55.7M YoY; includes $105M gain on sale of priority review voucher.
- First product revenue $0.6M from XOLREMDI launch following FDA approval in April 2024 for WHIM syndrome.
- Cash, equivalents, marketable securities $169.5M; operating runway into late 2025 (excl. future revenue).
- Positive interim Phase 2 data for mavorixafor in chronic neutropenia; full results expected Nov 2024; Phase 3 4WARD trial started.
- Plans to submit EMA approval for mavorixafor in WHIM syndrome by early 2025.

## SEC filing metadata
- accession: 0001628280-24-035848
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828024035848/0001628280-24-035848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828024035848/xfor-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035848
- JSON: https://secwatch.observer/filing/0001628280-24-035848.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.